BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
Portfolio Pulse from
Kahn Swick & Foti, LLC is investigating the proposed sale of bluebird bio, Inc. to Carlyle Group and SK Capital Partners. The deal offers bluebird shareholders $3.00 per share in cash and a contingent value right of $6.84 per share.
February 25, 2025 | 12:45 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Kahn Swick & Foti, LLC is investigating the proposed sale of bluebird bio, Inc. to Carlyle Group and SK Capital Partners. The investigation focuses on the adequacy of the price and process of the sale.
The investigation by Kahn Swick & Foti, LLC into the sale of bluebird bio raises concerns about the adequacy of the price and process, which could lead to uncertainty and potential delays in the transaction, negatively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100